• Ceftolozane/Tazobactam: Mechanisms and PK/PD Evidence

  2026-08-15

  The reference review integrates chemistry, antibacterial mechanisms, susceptibility data, pharmacokinetics, animal models, clinical trials, and safety findings for ceftolozane/tazobactam. Its main contribution is showing how PBP targeting, β-lactamase coverage, and time-dependent pharmacodynamics explain activity against important resistant Gram-negative pathogens, particularly Pseudomonas aeruginosa.

• Simvastatin (Zocor) Cell Assay Workflows

  2026-08-14

  Build more reproducible lipid-metabolism and liver-cancer assays with a controlled Simvastatin (Zocor) dosing, sampling, and validation workflow. The guide also shows how stress-granule and translation measurements from ALS research can improve mechanistic interpretation without overstating what simvastatin has been shown to do.

• Annexin V-Cy5/DAPI Apoptosis Kit Workflow

  2026-08-14

  Build a rapid, two-parameter cell death workflow that separates viable, apoptotic, and membrane-compromised populations in 10–20 minutes. Applied to Ph+ ALL research, the assay links P2RX1-driven mitochondrial stress and tyrosine kinase inhibitor response to an actionable apoptosis readout.

• BRD4770: A G9a Histone Methyltransferase Inhibitor

  2026-08-13

  BRD4770 is a focused small-molecule probe for connecting G9a activity with H3K9 methylation, senescence, and tumor-cell growth. This workflow-oriented guide shows how to handle its unusual solubility profile, build time-resolved assays, and translate breast-cancer pathway findings into carefully bounded PANC-1 experiments.

• BRD4770 and the Translational Logic of G9a Inhibition

  2026-08-13

  BRD4770 offers a practical way to interrogate G9a-driven H3K9 methylation, senescence, and tumor-cell fitness. This thought-leadership analysis connects its PANC-1 evidence with breast cancer findings on the BRD4–RAC1–c-MYC–G9a–FTH1 network, while separating established observations from translational hypotheses.

• Y-27632 dihydrochloride for Organoid Workflows

  2026-08-12

  Y-27632 dihydrochloride is a selective ROCK inhibitor that can improve post-dissociation cell recovery while providing a controllable way to study cytoskeletal remodeling. This guide connects practical ROCK inhibition workflows with the Paneth-cell and intestinal stem-cell findings reported in a recent Nature Communications study.

• WM-8014: A Practical KAT6A Inhibitor Workflow

  2026-08-12

  WM-8014 combines nanomolar biochemical potency with reversible, acetyl-CoA-competitive inhibition to support cleaner studies of KAT6A/B biology. This guide translates its use into cell-cycle, senescence, CRISPR-screen validation, and tumor-growth workflows while addressing solubility and exposure-design limitations.

• mPTP–mtDNA Signaling in Ferroptosis

  2026-08-11

  A 2026 Advanced Science study identifies CypD-dependent mitochondrial permeability transition pore opening as a key route for oxidized mitochondrial DNA release during ferroptosis. The work connects mitochondrial swelling to cGAS–STING activation, ferritinophagy, and tumor suppression, providing a mechanistic framework for interpreting mitochondria-dependent ferroptotic signaling.

• Myriocin Workflows for SPT and Mitochondrial Assays

  2026-08-11

  Myriocin gives researchers a direct way to perturb de novo sphingolipid synthesis while measuring proliferation, cell-cycle signaling, and mitochondrial performance. This workflow-oriented guide connects selective SPT inhibition with lipidomics, cancer models, immune studies, and the mitochondrial assays highlighted in recent yeast longevity research.

• Ginkgo Compound Cocktail Improves Yeast Longevity

  2026-08-10

  This study combines LC–MS/MS profiling, network pharmacology, and yeast aging assays to identify a four-compound Ginkgo biloba cocktail that improves mitochondrial function and extends chronological lifespan. Its main innovation is the experimental reduction of a complex botanical extract into a synergistic combination of quercetin, rutin, ginkgolide B, and isorhamnetin, while linking the phenotype to oxidative stress and mitochondrial endpoints.

• mTORC1 Oscillations Control Mitosis and Autophagy

  2026-08-09

  Joshi and colleagues show that mTORC1 activity is dynamically regulated across the cell cycle, reaching its highest level in S/G2 and its lowest level in mitosis and G1. The study links these oscillations to S-phase and G2 progression, Chk1/Wee1-dependent mitotic entry, and phase-specific sensitivity to autophagy induction.

• Myriocin as a Causal Probe of Sphingolipid Biology

  2026-08-08

  Myriocin is a potent serine palmitoyltransferase inhibitor that can turn broad mitochondrial and longevity phenotypes into testable sphingolipid hypotheses. This article connects a Ginkgo biloba yeast study with rigorous assay design, mechanistic controls, and translational limitations.

• Nanoparticle Uptake by Human Corneal Epithelial Cells

  2026-08-07

  This 2024 study shows that nanoparticle size and surface chemistry shape how PLGA nanoparticles interact with human corneal epithelial cells. Its in vitro model identifies energy-dependent uptake, with macropinocytosis and caveolae-mediated endocytosis as dominant pathways, providing design guidance for topical ocular delivery systems.

• Quercetin as a PI3K Inhibitor: Optimized Workflows for Cance

  2026-08-07

  Quercetin stands out as a robust PI3K inhibitor and apoptosis inducer in experimental cancer and neuroinflammation models. This article demystifies stepwise protocols, troubleshooting, and cross-domain applications, drawing on the latest reference study and real-world lab scenarios.

• Imatinib (STI571): Streamlining Tumor Microenvironment Assay

  2026-08-06

  Imatinib (STI571) empowers researchers to dissect tyrosine kinase signaling in complex tumor models, enabling high-fidelity signal transduction and cancer biology research. Discover protocol enhancements, troubleshooting strategies, and the impact of stromal components on kinase inhibitor response.

16079 records 1/1072 page Next 12345 下5页 Last page